The Correlation Between Anemia of Chronic Diseases, Hepcidin and Vitamin D in IBD Patients
NCT ID: NCT03145896
Last Updated: 2017-05-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
40 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-06-01
Study Completion Date
2018-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Crohn's disease (CD) and ulcerative colitis (UC) are chronic gastrointestinal diseases characterized by relapsing and remitting inflammation of the intestines Anemia may often complicate the course of inflammatory bowel disease (IBD). The cause of anemia in IBD is multifactorial In the chronically ill patients, it has been described that the mechanism underlying anemia involves hepcidin.A potential mechanism underlying anemia during an chronic disease is suggested by recent data demonstrating a hepcidin lowering effect of vitamin D
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Association Between Vitamin D Deficiency and Inflammatory Bowel Disease
NCT07259603
Inflammatory Bowel Diseases
NOT_YET_RECRUITING
Vitamin D Repletion and Maintenance in IBD: How Much and How Often
NCT03053414
Inflammatory Bowel Diseases
Vitamin D Deficiency
WITHDRAWN
NA
Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease
NCT05456932
Inflammatory Bowel Diseases
Iron-deficiency
Iron Deficiency Anemia
UNKNOWN
PHASE4
Vitamin D Status in Inflammatory Bowel Disease
NCT03496246
Vitamin D Deficiency
Inflammatory Bowel Diseases
UNKNOWN
NA
Vitamin D in Pediatric Crohn's Disease
NCT01187459
Vitamin D Deficiency
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Crohn's disease (CD) and ulcerative colitis (UC) are chronic gastrointestinal diseases characterized by relapsing and remitting inflammation of the intestines . Anemia may often complicate the course of inflammatory bowel disease (IBD) . A recent systematic review showed that anemia is common and may affect roughly 17% of patients with IBD .
The cause of anemia in IBD is multifactorial. The most common cause for anemia in IBD patients is iron deficiency anemia (IDA) secondary to increased blood loss from inflamed gastrointestinal mucosa and impaired absorption of iron. The anemia can be macrocytic due to impaired absorption of other nutrients including folate and cobalamin. Other causes are anemia due to medication (such as sulfasalazine) and anemia of chronic disease (ACD) .
ACD is characterized by normochromic, normocytic or mildly microcytic erythrocytes, low or normal serum iron and total iron-binding capacity, normal or increased iron stores reflected by elevated ferritin levels, low transferrin levels, and an inappropriately low reticulocyte response relative to the degree of anemia. ACD is unresponsive to treatment with iron, vitamin B12 or folic acid.
In the chronically ill patients, it has been described that the mechanism underlying anemia involves hepcidin.
Hepcidin, a β-defensin-like antimicrobial peptide, is part of the innate immune system and thus constitutes the first-line defense against infections. In vivo and in vitro studies have demonstrated that hepcidin is active against Gram-positive and Gram-negative bacteria as well as yeasts . In addition to its antimicrobial activity, it acts as an iron regulatory hormone. Increased hepcidin synthesis inhibits iron flow into plasma from macrophages that have taken up and degraded senescent erythrocytes as well as their hemoglobin, and also from small intestinal epithelial cells involved in the absorption of dietary iron . This iron release from cytoplasmic stores is prevented by binding of hepcidin to the iron exporter protein ferroportin. Ferroportin is internalized and degraded upon hepcidin activity.
Hepcidin is produced and secreted mainly by hepatocytes, and to a lesser extent by macrophages and adipocytes . Its synthesis is regulated by iron, erythropoietic activity and inflammation . Hepcidin expression is down-regulated in anemia with concomitant iron deficiency. Thus, ferroportin is not internalized from the cell membrane and iron can be transported from stores to the plasma to provide heme synthesis and erythropoiesis with more iron. On the other hand during anemia of chronic diseases (without significant iron deficiency), hepcidin expression is even increased, which may explain why iron is "trapped" intracellularly under these conditions.
In IBD (similar to other chronic inflammatory disease or infections), it can be assumed that inflammation increases hepcidin expression and synthesis as hepcidin also is an "acute phase protein" . This induction of hepcidin protein synthesis is at least partially mediated by interleukin-6 via its receptor and subsequent intracellular signal transduction via signal transducer and activator of transcription-3 (STAT3).
In the study of Pantelis et el it was found that the median hepcidin level were significantly higher in patients with IBD compared with healthy controls In a recent study by Basseri and coworkers, a positive correlation between serum hepcidin and IL-6 levels in IBD patients was confirmed. The authors further detected a negative correlation between serum hepcidin concentration and Hgb levels.
A potential mechanism underlying anemia during an chronic disease is suggested by recent data demonstrating a hepcidin lowering effect of vitamin D.
In the setting of chronic kidney disease patients, it was shown that vitamin D is inversely associated with hepcidin concentrations, and positively associated with hemoglobin and iron concentrations. Importantly, vitamin D has been reported to decrease inflammatory cytokines implicated in the pathophysiology of anemia during inflammation, and suppress expression of hepcidin mRNA. Additionally, oral administration of vitamin D in healthy adult volunteers lowered serum levels of hepcidin by 50% compared to baseline levels within 24 hours and persisted for 72 hours.
These initial results seem promising; but thus far the association between IBD, vitamin D status and anemia has never been established in the pediatric population, nor has the connection between these hormones and the efficacy of iron supplementation therapy. Controlled studies are warranted to determine this link and, thereafter, investigate the possible therapeutic potential of vitamin D supplementation
Aim:
To examine the association between hepcidin, IL6, vitamin D and anemia in children and adolescence with IBD and to study the possible effect of vitamin D supplementation on hepcidin level in IBD patients.
Hypothesis:
We hypothesize that in patients with parameters of anemia of chronic disease hepcidine level will be high and vitamin D level will be low. Supplementation of vitamin D will lower hepcidin levels and improve the anemia.
Study population and study design:
This is a prospective study. It will take place in the Pediatric Gastroenterology Unit at Dana- Dwek Children's hospital.
The study population will consists of 40 newly diagnosed IBD Patients, male and female, age 6-18. We will recruit all patients that are suspicious to have IBD based on their clinical and laboratory evaluation in their first diagnostic colonoscopy.
Each participant in the study will provide written informed consent at the beginning of the study.
We will document the participant's age, sex, anthropometric measurements (weight, height).
Each participant will complete a questionnaire that records personal lifestyle and demographic information, physical activity and sun exposure. Medical data (medical background, medication, sign and symptoms, severity of disease) will be collected from the patient's medical file.
We will take from each participant blood sample (approximately 10cc), to test levels of 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin, hematocrit (Hct), RBC, MCV, RDW, serum iron, total-iron-binding capacity, hepcidin, transferrin, soulable transferrin receptor, ferritin and IL6. We will document calprotectin level if available.
Before discharge home all patients will be taught to take 5000 unit of vitamin D (25(OH)D) daily, for the next 2 week . All patients will be invited for follow-up in 2 weeks to get the histopathology result. In this encounter we will take again blood sample for 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin, hematocrit (Hct), RBC, MCV, RDW, serum iron, total-iron-binding capacity, hepcidin, transferrin, ferritin soulable transferrin receptor and IL6.
All the data will be coded and the questionnaires will be kept in a locked place.
The concentration of 25(OH)D will be measured by radioimmunoassay. Levels of Hepcidin will be measured by a commercial kit.
Blood sample collection and questionnaire completion will be done in 2 days. (Visits will be appointed as the usual appointments after endoscopy in our clinic).
Study data analysis will be completed within a year.
The cause of anemia in IBD is multifactorial. The most common cause for anemia in IBD patients is iron deficiency anemia (IDA) secondary to increased blood loss from inflamed gastrointestinal mucosa and impaired absorption of iron. The anemia can be macrocytic due to impaired absorption of other nutrients including folate and cobalamin. Other causes are anemia due to medication (such as sulfasalazine) and anemia of chronic disease (ACD) .
ACD is characterized by normochromic, normocytic or mildly microcytic erythrocytes, low or normal serum iron and total iron-binding capacity, normal or increased iron stores reflected by elevated ferritin levels, low transferrin levels, and an inappropriately low reticulocyte response relative to the degree of anemia. ACD is unresponsive to treatment with iron, vitamin B12 or folic acid.
In the chronically ill patients, it has been described that the mechanism underlying anemia involves hepcidin.
Hepcidin, a β-defensin-like antimicrobial peptide, is part of the innate immune system and thus constitutes the first-line defense against infections. In vivo and in vitro studies have demonstrated that hepcidin is active against Gram-positive and Gram-negative bacteria as well as yeasts . In addition to its antimicrobial activity, it acts as an iron regulatory hormone. Increased hepcidin synthesis inhibits iron flow into plasma from macrophages that have taken up and degraded senescent erythrocytes as well as their hemoglobin, and also from small intestinal epithelial cells involved in the absorption of dietary iron . This iron release from cytoplasmic stores is prevented by binding of hepcidin to the iron exporter protein ferroportin. Ferroportin is internalized and degraded upon hepcidin activity.
Hepcidin is produced and secreted mainly by hepatocytes, and to a lesser extent by macrophages and adipocytes . Its synthesis is regulated by iron, erythropoietic activity and inflammation . Hepcidin expression is down-regulated in anemia with concomitant iron deficiency. Thus, ferroportin is not internalized from the cell membrane and iron can be transported from stores to the plasma to provide heme synthesis and erythropoiesis with more iron. On the other hand during anemia of chronic diseases (without significant iron deficiency), hepcidin expression is even increased, which may explain why iron is "trapped" intracellularly under these conditions.
In IBD (similar to other chronic inflammatory disease or infections), it can be assumed that inflammation increases hepcidin expression and synthesis as hepcidin also is an "acute phase protein" . This induction of hepcidin protein synthesis is at least partially mediated by interleukin-6 via its receptor and subsequent intracellular signal transduction via signal transducer and activator of transcription-3 (STAT3).
In the study of Pantelis et el it was found that the median hepcidin level were significantly higher in patients with IBD compared with healthy controls In a recent study by Basseri and coworkers, a positive correlation between serum hepcidin and IL-6 levels in IBD patients was confirmed. The authors further detected a negative correlation between serum hepcidin concentration and Hgb levels.
A potential mechanism underlying anemia during an chronic disease is suggested by recent data demonstrating a hepcidin lowering effect of vitamin D.
In the setting of chronic kidney disease patients, it was shown that vitamin D is inversely associated with hepcidin concentrations, and positively associated with hemoglobin and iron concentrations. Importantly, vitamin D has been reported to decrease inflammatory cytokines implicated in the pathophysiology of anemia during inflammation, and suppress expression of hepcidin mRNA. Additionally, oral administration of vitamin D in healthy adult volunteers lowered serum levels of hepcidin by 50% compared to baseline levels within 24 hours and persisted for 72 hours.
These initial results seem promising; but thus far the association between IBD, vitamin D status and anemia has never been established in the pediatric population, nor has the connection between these hormones and the efficacy of iron supplementation therapy. Controlled studies are warranted to determine this link and, thereafter, investigate the possible therapeutic potential of vitamin D supplementation
Aim:
To examine the association between hepcidin, IL6, vitamin D and anemia in children and adolescence with IBD and to study the possible effect of vitamin D supplementation on hepcidin level in IBD patients.
Hypothesis:
We hypothesize that in patients with parameters of anemia of chronic disease hepcidine level will be high and vitamin D level will be low. Supplementation of vitamin D will lower hepcidin levels and improve the anemia.
Study population and study design:
This is a prospective study. It will take place in the Pediatric Gastroenterology Unit at Dana- Dwek Children's hospital.
The study population will consists of 40 newly diagnosed IBD Patients, male and female, age 6-18. We will recruit all patients that are suspicious to have IBD based on their clinical and laboratory evaluation in their first diagnostic colonoscopy.
Each participant in the study will provide written informed consent at the beginning of the study.
We will document the participant's age, sex, anthropometric measurements (weight, height).
Each participant will complete a questionnaire that records personal lifestyle and demographic information, physical activity and sun exposure. Medical data (medical background, medication, sign and symptoms, severity of disease) will be collected from the patient's medical file.
We will take from each participant blood sample (approximately 10cc), to test levels of 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin, hematocrit (Hct), RBC, MCV, RDW, serum iron, total-iron-binding capacity, hepcidin, transferrin, soulable transferrin receptor, ferritin and IL6. We will document calprotectin level if available.
Before discharge home all patients will be taught to take 5000 unit of vitamin D (25(OH)D) daily, for the next 2 week . All patients will be invited for follow-up in 2 weeks to get the histopathology result. In this encounter we will take again blood sample for 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin, hematocrit (Hct), RBC, MCV, RDW, serum iron, total-iron-binding capacity, hepcidin, transferrin, ferritin soulable transferrin receptor and IL6.
All the data will be coded and the questionnaires will be kept in a locked place.
The concentration of 25(OH)D will be measured by radioimmunoassay. Levels of Hepcidin will be measured by a commercial kit.
Blood sample collection and questionnaire completion will be done in 2 days. (Visits will be appointed as the usual appointments after endoscopy in our clinic).
Study data analysis will be completed within a year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
IBD
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
OTHER
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IBD patients with Vitamin D treatment
Group Type
ACTIVE_COMPARATOR
vitamin D
Intervention Type
DIETARY_SUPPLEMENT
After the gastroscopy all patients will be taught to take 4000 unit of vitamin D (25(OH)D) daily (not a specific brand) , for the next 2 week. All patients will be invited for follow-up in 2 weeks to get the histopathology result. In this encounter we will take again blood sample for 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin. a control group will not take the Vitamin D supplements.
IBD patients with no Vitamin D treatment
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
vitamin D
After the gastroscopy all patients will be taught to take 4000 unit of vitamin D (25(OH)D) daily (not a specific brand) , for the next 2 week. All patients will be invited for follow-up in 2 weeks to get the histopathology result. In this encounter we will take again blood sample for 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin. a control group will not take the Vitamin D supplements.
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with newly diagnosed IBD based on histopathology.
Exclusion Criteria
* Patients that their histopathology will confirm eventually different diagnosis.
* Participants that are receiving medications known to alter vitamin D metabolism or have hepatic or renal disease
* Participants that suffer from hemoglobinopaties, bone marrow failure, or receive bone marrow suppressing agents
* Participants that went through a recent surgical procedure, or needed blood transfusion for any reason
* Participants that are receiving medications known to alter vitamin D metabolism or have hepatic or renal disease
* Participants that suffer from hemoglobinopaties, bone marrow failure, or receive bone marrow suppressing agents
* Participants that went through a recent surgical procedure, or needed blood transfusion for any reason
Minimum Eligible Age
5 Years
Maximum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tel-Aviv Sourasky Medical Center
OTHER_GOV
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
michal roll
Phd
Responsibility Role
PRINCIPAL_INVESTIGATOR
References
Explore related publications, articles, or registry entries linked to this study.
Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002 Aug 8;347(6):417-29. doi: 10.1056/NEJMra020831. No abstract available.
Reference Type
BACKGROUND
Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis. 2000 May;6(2):142-150; discussion 151. doi: 10.1097/00054725-200005000-00013.
Reference Type
BACKGROUND
de la Morena F, Gisbert JP. [Anemia and inflammatory bowel disease]. Rev Esp Enferm Dig. 2008 May;100(5):285-93. Spanish.
Reference Type
BACKGROUND
de Silva AD, Mylonaki M, Rampton DS. Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy. Inflamm Bowel Dis. 2003 Sep;9(5):316-20. doi: 10.1097/00054725-200309000-00005.
Reference Type
BACKGROUND
Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008 May;103(5):1299-307. doi: 10.1111/j.1572-0241.2008.01846.x.
Reference Type
BACKGROUND
Basseri RJ, Nemeth E, Vassilaki ME, Basseri B, Enayati P, Shaye O, Bourikas LA, Ganz T, Papadakis KA. Hepcidin is a key mediator of anemia of inflammation in Crohn's disease. J Crohns Colitis. 2013 Sep;7(8):e286-91. doi: 10.1016/j.crohns.2012.10.013. Epub 2012 Dec 6.
Reference Type
BACKGROUND
Yapakci E, Tarcan A, Celik B, Ozbek N, Gurakan B. Serum pro-hepcidin levels in term and preterm newborns with sepsis. Pediatr Int. 2009 Apr;51(2):289-92. doi: 10.1111/j.1442-200X.2008.02688.x.
Reference Type
BACKGROUND
Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009;122(2-3):78-86. doi: 10.1159/000243791. Epub 2009 Nov 10.
Reference Type
BACKGROUND
Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 Mar;35(3):155-61. doi: 10.1016/j.tips.2014.01.004. Epub 2014 Feb 17.
Reference Type
BACKGROUND
Ross SL, Tran L, Winters A, Lee KJ, Plewa C, Foltz I, King C, Miranda LP, Allen J, Beckman H, Cooke KS, Moody G, Sasu BJ, Nemeth E, Ganz T, Molineux G, Arvedson TL. Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. Cell Metab. 2012 Jun 6;15(6):905-17. doi: 10.1016/j.cmet.2012.03.017.
Reference Type
BACKGROUND
Dudkowiak R, Neubauer K, Poniewierka E. Hepcidin and its role in inflammatory bowel disease. Adv Clin Exp Med. 2013 Jul-Aug;22(4):585-91.
Reference Type
BACKGROUND
Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003 Apr 1;101(7):2461-3. doi: 10.1182/blood-2002-10-3235. Epub 2002 Nov 14.
Reference Type
BACKGROUND
Theurl I, Schroll A, Nairz M, Seifert M, Theurl M, Sonnweber T, Kulaksiz H, Weiss G. Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo. Haematologica. 2011 Dec;96(12):1761-9. doi: 10.3324/haematol.2011.048926. Epub 2011 Aug 22.
Reference Type
BACKGROUND
Ferrucci L, Semba RD, Guralnik JM, Ershler WB, Bandinelli S, Patel KV, Sun K, Woodman RC, Andrews NC, Cotter RJ, Ganz T, Nemeth E, Longo DL. Proinflammatory state, hepcidin, and anemia in older persons. Blood. 2010 May 6;115(18):3810-6. doi: 10.1182/blood-2009-02-201087. Epub 2010 Jan 15.
Reference Type
BACKGROUND
Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004 May;113(9):1271-6. doi: 10.1172/JCI20945.
Reference Type
BACKGROUND
Oustamanolakis P, Koutroubakis IE, Messaritakis I, Malliaraki N, Sfiridaki A, Kouroumalis EA. Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011 Mar;23(3):262-8. doi: 10.1097/MEG.0b013e328343b885.
Reference Type
BACKGROUND
Smith EM, Alvarez JA, Martin GS, Zughaier SM, Ziegler TR, Tangpricha V. Vitamin D deficiency is associated with anaemia among African Americans in a US cohort. Br J Nutr. 2015 Jun 14;113(11):1732-40. doi: 10.1017/S0007114515000999. Epub 2015 Apr 16.
Reference Type
BACKGROUND
Bacchetta J, Zaritsky JJ, Sea JL, Chun RF, Lisse TS, Zavala K, Nayak A, Wesseling-Perry K, Westerman M, Hollis BW, Salusky IB, Hewison M. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol. 2014 Mar;25(3):564-72. doi: 10.1681/ASN.2013040355. Epub 2013 Nov 7.
Reference Type
BACKGROUND
Moran-Lev H, Galai T, Yerushalmy-Feler A, Weisman Y, Anafy A, Deutsch V, Cipok M, Lubetzky R, Cohen S. Vitamin D Decreases Hepcidin and Inflammatory Markers in Newly Diagnosed Inflammatory Bowel Disease Paediatric Patients: A Prospective Study. J Crohns Colitis. 2019 Sep 27;13(10):1287-1291. doi: 10.1093/ecco-jcc/jjz056.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TASMC-15-SC-0778-CTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Vitamin D Supplementation in Adult Crohn's Disease
NCT01369667
COMPLETED
PHASE4
Vitamin D and Disease Activity in Ulcerative Colitis
NCT02717897
COMPLETED
Vitamin D Treatment in Ulcerative Colitis
NCT01640496
WITHDRAWN
NA
Adjunctive Treatment With Vitamin D3 in Patients With Active IBD
NCT04225819
SUSPENDED
NA
Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D
NCT01877577
COMPLETED
NA
Vitd and Barrier Function in IBD
NCT01792388
COMPLETED
PHASE4
Weekly Vitamin D in Pediatric IBD
NCT02076750
COMPLETED
PHASE1/PHASE2
Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis
NCT00152841
TERMINATED
PHASE2
Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases
NCT03841045
UNKNOWN
Oxidative Stress and Inflammation Caused by Intravenous Iron in Crohn's Disease Patients With Iron Deficiency Anemia
NCT01823029
COMPLETED
NA
The Prospective Improved Vitamin D Study for Inflammatory Bowel Disease Patients
NCT07177157
NOT_YET_RECRUITING
PHASE1
Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease
NCT01046773
TERMINATED
PHASE1
Effect of Vitamin D Supplementation on Infliximab Response in Patients With Crohn's Disease
NCT04606017
COMPLETED
Ulcerative Colitis and Vitamin D Supplementation
NCT01846026
WITHDRAWN
PHASE1/PHASE2
Vitamin D Supplementation in Crohn's Patients
NCT00742781
COMPLETED
PHASE1
Vitamin D Regulation of Gut Specific B Cells and Antibodies Targeting Gut Bacteria in Inflammatory Bowel Disease
NCT04828031
COMPLETED
PHASE1
Observation of the Effect of Vitamin D Supplementation on Chronic Course of Patients With Ulcerative Colitis Based on Vitamin D Receptor Fok I Gene Polymorphism
NCT04309058
UNKNOWN
EARLY_PHASE1
Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy.
NCT05581420
UNKNOWN
NA
Cytokines and Genes in Therapeutic Response in Crohn's Disease
NCT03266471
COMPLETED
Exploring the Effects of Vitamin D Supplementation on the Chronic Course of Patients With Crohn's Disease With Vitamin D Deficiency
NCT04308850
UNKNOWN
EARLY_PHASE1
The Impact of Vitamin D on Disease Activity in Crohn's Disease
NCT01864616
TERMINATED
NA
Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis
NCT00586599
COMPLETED
NA
Can Vitamin D Supplementation in People With Crohn's Disease Improve Symptoms as an Adjunct Therapy?
NCT03718182
UNKNOWN
PHASE4
Effect of Vitamin D Supplementation on Vedolizumab Response in Patients With Ulcerative Colitis
NCT05649462
COMPLETED
Vitamin D Treatment for Crohn´s Disease
NCT00132184
UNKNOWN
PHASE2/PHASE3